Corrigendum to "IP1867B suppresses the insulin-like growth factor 1receptor (IGF1R) ablating epidermal growth factor receptor inhibitorresistance in adult high grade gliomas." [Cancer Lett. 458C (2019) 29–38]

Mihajluk K[1], Simms C[1], Reay M[1], Madureira P[2]. Howarth A[1], Murray P[1]. Nasser S[1], Duckworth CA[3], Pritchard DM[3], Pilkington GJ[1] and Hill R[1.]

1. Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, IBBS, University of Portsmouth, PO1 2DT, UK.
2. Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, Room 3.4, 8005-139 Faro, Portugal.
3. Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, L69 3GE, UK.

In the article above, we, the authors, discovered that a single microscopy panel was inadvertently placed in Figure 1f, using the SEBTA-023 panel twice instead of the SEBTA-003 representative image. We discovered that an actin western blot loading control data associated with Figure 3a was also incorrectly placed in Figure 5i. We retrieved the original actin western blot data linked to Figure 5i and corrected this error.

Neither correction alter the conclusions of the original paper; however, we sincerely apologize for any confusion that this may have caused.

Figure 1.

f).

Figure 1f). Representative microscopy images for each biopsy-derived aHGG cell line 24 hours post IP1867B treatment (40 x magnification).

Figure 5.

i).

Figure 5i). Representative immunoblot for EGFR and β-actin following *in vivo* treatment with each therapeutic at day 19.

Supplemental Figure 6.

i).

i).

Supplemental Figure 6. Full uncropped immunblots for the data shown in Figure 5i.